Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 24;184(13):3452–3466.e18. doi: 10.1016/j.cell.2021.05.032

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Elsevier Inc.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Induction of the open conformation of the RBD by divalent enhancing antibodies

(A) The binding of antibodies specific to the open RBD (H014) or the open and closed RBD (C009, C144, and C135) against spike transfectants was analyzed in the presence of the indicated enhancing antibodies (3 μg/mL). ACE2 binding to spike protein was also analyzed. The non-enhancing anti-NTD antibodies 4A8 and 4A2 were used as controls. Relative antibody- or ACE2-binding levels observed in the presence of anti-NTD antibodies are shown.

(B) H014 antibody binding and ACE2 binding to spike protein in the presence of indicated antibodies are shown. The correlation coefficient between them is indicated.

(C) H014 antibody binding and ACE2 binding to spike protein in the presence of various concentrations of Fab and F(ab′)₂ and fragments of the enhancing COV2-2490 antibody.

(D) A model of spike protein bound with divalent enhancing antibodies (8D2 and COV2-2490). Spike protein and Fab complexes demonstrated in Figure 5D were used as a template for the models.

See also Figure S5.